Da Volterra

Da Volterra is a clinical stage biotech company located in Paris, France, and developing novel microbiota-protective therapies. Da Volterra’s lead product, DAV132, is a Phase 3-ready first-in-class colon-targeted adsorbent developed in several indications associated to the preservation of a healthy microbiota in patients under antibiotic treatments. This includes the prevention of C. difficile infection (CDI) and resistant bacteria colonization in patients who previously suffered from CDI and in immuno-compromised patients, prevention of Graft-vs-Host Disease in patients with hematologic malignancies, as well as preservation of Immune Checkpoint Inhibitors’ efficacy in cancer patients receiving antibiotics. Website: https://davolterra.com/ Contact: [email protected]